Official reprint from UpToDate®
www.uptodate.com ©2016 UpToDate®

Mechanisms of atrial fibrillation

Brian Olshansky, MD
Rishi Arora, MD
Section Editors
Bradley P Knight, MD, FACC
Hugh Calkins, MD
Deputy Editor
Gordon M Saperia, MD, FACC


Atrial fibrillation (AF) is a most common cardiac arrhythmia. The chance of developing AF is tied closely to age, with AF rare before the age of 50 years. In addition to age, there are many types of cardiac and medical conditions that are also closely linked to AF. These include hypertension, coronary artery disease, heart failure, valvular heart disease, obesity, and sleep-apnea syndrome. It is well established that high levels of alcohol can increase the probability of developing AF, and that hyperthyroidism can cause AF. Evidence for caffeine and energy drinks, while suspected, is questionable [1]. It is also well established that AF is more common in individuals who have a first-degree relative who developed AF at a young age. (See "Epidemiology of and risk factors for atrial fibrillation".)

The precise mechanisms by which age and the other conditions listed above increase the propensity for development of AF are understood poorly (figure 1). However, these conditions may impact the triggers for AF, which commonly arise in the pulmonary veins or the substrate for maintenance of AF, which broadly relates to atrial size and the extent of fibrosis. Some of the factors that may play a role in the mechanisms of AF include autonomic tone, inflammation, atrial pressure and wall stress, and genetics. (See "Epidemiology of and risk factors for atrial fibrillation", section on 'Other factors'.)

This topic will provide a broad overview of the current understanding of the mechanisms of AF. This discussion will provide a relatively simplistic approach to a complex topic. The reader will be referred to a rapidly growing literature on this topic, including some comprehensive reviews [2].


The following terms are defined to help the reader’s understanding of the material below:

Trigger – a rapidly firing focus often arising in the pulmonary veins that can initiate atrial fibrillation (AF).


Subscribers log in here

To continue reading this article, you must log in with your personal, hospital, or group practice subscription. For more information or to purchase a personal subscription, click below on the option that best describes you:
Literature review current through: Sep 2016. | This topic last updated: Nov 25, 2015.
The content on the UpToDate website is not intended nor recommended as a substitute for medical advice, diagnosis, or treatment. Always seek the advice of your own physician or other qualified health care professional regarding any medical questions or conditions. The use of this website is governed by the UpToDate Terms of Use ©2016 UpToDate, Inc.
  1. Turagam MK, Velagapudi P, Kocheril AG, Alpert MA. Commonly consumed beverages in daily life: do they cause atrial fibrillation? Clin Cardiol 2015; 38:317.
  2. Schotten U, Verheule S, Kirchhof P, Goette A. Pathophysiological mechanisms of atrial fibrillation: a translational appraisal. Physiol Rev 2011; 91:265.
  3. Allessie MA, Konings K, Kirchhof CJ, Wijffels M. Electrophysiologic mechanisms of perpetuation of atrial fibrillation. Am J Cardiol 1996; 77:10A.
  4. Arnsdorf, MF. Electrophysiology and biophysics of cardiac excitation. In: Current Concepts of Cardiovascular Physiology, 1st ed, Garfein, O (Eds), Academic Press, Orlando 1990. p.465.
  5. Fozzard, HA, Arnsdorf, MF. Cardiac electrophysiology. In: The Heart and Cardiovascular System, Fozzard, HA, Haber, E, Jennings, RB, Katz, AM, Morgan, HE (Eds), Raven Press, New York 1991. p.63.
  6. Allessie MA, Boyden PA, Camm AJ, et al. Pathophysiology and prevention of atrial fibrillation. Circulation 2001; 103:769.
  7. SCHERF D. Studies on auricular tachycardia caused by aconitine administration. Proc Soc Exp Biol Med 1947; 64:233.
  8. Kalifa J, Jalife J, Zaitsev AV, et al. Intra-atrial pressure increases rate and organization of waves emanating from the superior pulmonary veins during atrial fibrillation. Circulation 2003; 108:668.
  9. Thijssen VL, Ausma J, Liu GS, et al. Structural changes of atrial myocardium during chronic atrial fibrillation. Cardiovasc Pathol 2000; 9:17.
  10. Wijffels MC, Kirchhof CJ, Dorland R, Allessie MA. Atrial fibrillation begets atrial fibrillation. A study in awake chronically instrumented goats. Circulation 1995; 92:1954.
  11. Klein GJ, Bashore TM, Sellers TD, et al. Ventricular fibrillation in the Wolff-Parkinson-White syndrome. N Engl J Med 1979; 301:1080.
  12. Elvan A, Huang XD, Pressler ML, Zipes DP. Radiofrequency catheter ablation of the atria eliminates pacing-induced sustained atrial fibrillation and reduces connexin 43 in dogs. Circulation 1997; 96:1675.
  13. van der Velden HM, Ausma J, Rook MB, et al. Gap junctional remodeling in relation to stabilization of atrial fibrillation in the goat. Cardiovasc Res 2000; 46:476.
  14. Aimé-Sempé C, Folliguet T, Rücker-Martin C, et al. Myocardial cell death in fibrillating and dilated human right atria. J Am Coll Cardiol 1999; 34:1577.
  15. Elvan A, Wylie K, Zipes DP. Pacing-induced chronic atrial fibrillation impairs sinus node function in dogs. Electrophysiological remodeling. Circulation 1996; 94:2953.
  16. Daoud EG, Bogun F, Goyal R, et al. Effect of atrial fibrillation on atrial refractoriness in humans. Circulation 1996; 94:1600.
  17. Tieleman RG, Van Gelder IC, Crijns HJ, et al. Early recurrences of atrial fibrillation after electrical cardioversion: a result of fibrillation-induced electrical remodeling of the atria? J Am Coll Cardiol 1998; 31:167.
  18. Franz MR, Karasik PL, Li C, et al. Electrical remodeling of the human atrium: similar effects in patients with chronic atrial fibrillation and atrial flutter. J Am Coll Cardiol 1997; 30:1785.
  19. Pandozi C, Bianconi L, Villani M, et al. Electrophysiological characteristics of the human atria after cardioversion of persistent atrial fibrillation. Circulation 1998; 98:2860.
  20. Narayan SM, Krummen DE, Shivkumar K, et al. Treatment of atrial fibrillation by the ablation of localized sources: CONFIRM (Conventional Ablation for Atrial Fibrillation With or Without Focal Impulse and Rotor Modulation) trial. J Am Coll Cardiol 2012; 60:628.
  21. Haissaguerre M, Hocini M, Denis A, et al. Driver domains in persistent atrial fibrillation. Circulation 2014; 130:530.
  22. Climent AM, Guillem MS, Fuentes L, et al. Role of atrial tissue remodeling on rotor dynamics: an in vitro study. Am J Physiol Heart Circ Physiol 2015; 309:H1964.
  23. Lee S, Sahadevan J, Khrestian CM, et al. Simultaneous Biatrial High-Density (510-512 Electrodes) Epicardial Mapping of Persistent and Long-Standing Persistent Atrial Fibrillation in Patients: New Insights Into the Mechanism of Its Maintenance. Circulation 2015; 132:2108.
  24. Kuklik P, Lau DH, Ganesan AN, et al. High-density mapping of atrial fibrillation in a chronic substrate: evidence for distinct modes of repetitive wavefront propagation. Int J Cardiol 2015; 199:407.
  25. Allessie MA. Atrial fibrillation-induced electrical remodeling in humans: what is the next step? Cardiovasc Res 1999; 44:10.
  26. Wijffels MC, Kirchhof CJ, Dorland R, et al. Electrical remodeling due to atrial fibrillation in chronically instrumented conscious goats: roles of neurohumoral changes, ischemia, atrial stretch, and high rate of electrical activation. Circulation 1997; 96:3710.
  27. Fareh S, Villemaire C, Nattel S. Importance of refractoriness heterogeneity in the enhanced vulnerability to atrial fibrillation induction caused by tachycardia-induced atrial electrical remodeling. Circulation 1998; 98:2202.
  28. Raitt MH, Kusumoto W, Giraud G, McAnulty JH. Reversal of electrical remodeling after cardioversion of persistent atrial fibrillation. J Cardiovasc Electrophysiol 2004; 15:507.
  29. Brundel BJ, Van Gelder IC, Henning RH, et al. Ion channel remodeling is related to intraoperative atrial effective refractory periods in patients with paroxysmal and persistent atrial fibrillation. Circulation 2001; 103:684.
  30. Tieleman RG, De Langen C, Van Gelder IC, et al. Verapamil reduces tachycardia-induced electrical remodeling of the atria. Circulation 1997; 95:1945.
  31. Daoud EG, Knight BP, Weiss R, et al. Effect of verapamil and procainamide on atrial fibrillation-induced electrical remodeling in humans. Circulation 1997; 96:1542.
  32. Tse HF, Lau CP, Wang Q, et al. Effect of diltiazem on the recurrence rate of paroxysmal atrial fibrillation. Am J Cardiol 2001; 88:568.
  33. Tieleman RG, Blaauw Y, Van Gelder IC, et al. Digoxin delays recovery from tachycardia-induced electrical remodeling of the atria. Circulation 1999; 100:1836.
  34. Sticherling C, Oral H, Horrocks J, et al. Effects of digoxin on acute, atrial fibrillation-induced changes in atrial refractoriness. Circulation 2000; 102:2503.
  35. Vest JA, Wehrens XH, Reiken SR, et al. Defective cardiac ryanodine receptor regulation during atrial fibrillation. Circulation 2005; 111:2025.
  36. Nattel S, Burstein B, Dobrev D. Atrial remodeling and atrial fibrillation: mechanisms and implications. Circ Arrhythm Electrophysiol 2008; 1:62.
  37. Nakashima H, Kumagai K, Urata H, et al. Angiotensin II antagonist prevents electrical remodeling in atrial fibrillation. Circulation 2000; 101:2612.
  38. Goette A, Arndt M, Röcken C, et al. Regulation of angiotensin II receptor subtypes during atrial fibrillation in humans. Circulation 2000; 101:2678.
  39. Pedersen OD, Bagger H, Kober L, Torp-Pedersen C. Trandolapril reduces the incidence of atrial fibrillation after acute myocardial infarction in patients with left ventricular dysfunction. Circulation 1999; 100:376.
  40. Vermes E, Tardif JC, Bourassa MG, et al. Enalapril decreases the incidence of atrial fibrillation in patients with left ventricular dysfunction: insight from the Studies Of Left Ventricular Dysfunction (SOLVD) trials. Circulation 2003; 107:2926.
  41. Jayachandran JV, Zipes DP, Weksler J, Olgin JE. Role of the Na(+)/H(+) exchanger in short-term atrial electrophysiological remodeling. Circulation 2000; 101:1861.
  42. Sheng X, Scherlag BJ, Yu L, et al. Prevention and reversal of atrial fibrillation inducibility and autonomic remodeling by low-level vagosympathetic nerve stimulation. J Am Coll Cardiol 2011; 57:563.
  43. Scherlag BJ, Nakagawa H, Jackman WM, et al. Non-pharmacological, non-ablative approaches for the treatment of atrial fibrillation: experimental evidence and potential clinical implications. J Cardiovasc Transl Res 2011; 4:35.
  44. Lu Z, Scherlag BJ, Lin J, et al. Autonomic mechanism for initiation of rapid firing from atria and pulmonary veins: evidence by ablation of ganglionated plexi. Cardiovasc Res 2009; 84:245.
  45. Chou CC, Chen PS. New concepts in atrial fibrillation: neural mechanisms and calcium dynamics. Cardiol Clin 2009; 27:35.
  46. Shen MJ, Choi EK, Tan AY, et al. Neural mechanisms of atrial arrhythmias. Nat Rev Cardiol 2011; 9:30.
  47. Yamaguchi Y, Kumagai K, Nakashima H, Saku K. Long-term effects of box isolation on sympathovagal balance in atrial fibrillation. Circ J 2010; 74:1096.
  48. Coumel P. Autonomic influences in atrial tachyarrhythmias. J Cardiovasc Electrophysiol 1996; 7:999.
  49. Chen PS, Tan AY. Autonomic nerve activity and atrial fibrillation. Heart Rhythm 2007; 4:S61.
  50. Nemirovsky D, Hutter R, Gomes JA. The electrical substrate of vagal atrial fibrillation as assessed by the signal-averaged electrocardiogram of the P wave. Pacing Clin Electrophysiol 2008; 31:308.
  51. Sharifov OF, Fedorov VV, Beloshapko GG, et al. Roles of adrenergic and cholinergic stimulation in spontaneous atrial fibrillation in dogs. J Am Coll Cardiol 2004; 43:483.
  52. Hirose M, Carlson MD, Laurita KR. Cellular mechanisms of vagally mediated atrial tachyarrhythmia in isolated arterially perfused canine right atria. J Cardiovasc Electrophysiol 2002; 13:918.
  53. Crawford T, Chugh A, Good E, et al. Clinical value of noninducibility by high-dose isoproterenol versus rapid atrial pacing after catheter ablation of paroxysmal atrial fibrillation. J Cardiovasc Electrophysiol 2010; 21:13.
  54. Zimmermann M, Kalusche D. Fluctuation in autonomic tone is a major determinant of sustained atrial arrhythmias in patients with focal ectopy originating from the pulmonary veins. J Cardiovasc Electrophysiol 2001; 12:285.
  55. Hsieh MH, Chiou CW, Wen ZC, et al. Alterations of heart rate variability after radiofrequency catheter ablation of focal atrial fibrillation originating from pulmonary veins. Circulation 1999; 100:2237.
  56. Bettoni M, Zimmermann M. Autonomic tone variations before the onset of paroxysmal atrial fibrillation. Circulation 2002; 105:2753.
  57. Pappone C, Santinelli V, Manguso F, et al. Pulmonary vein denervation enhances long-term benefit after circumferential ablation for paroxysmal atrial fibrillation. Circulation 2004; 109:327.
  58. Verma A, Saliba WI, Lakkireddy D, et al. Vagal responses induced by endocardial left atrial autonomic ganglion stimulation before and after pulmonary vein antrum isolation for atrial fibrillation. Heart Rhythm 2007; 4:1177.
  59. Arruda M, Natale A. Ablation of permanent AF: adjunctive strategies to pulmonary veins isolation: targeting AF NEST in sinus rhythm and CFAE in AF. J Interv Card Electrophysiol 2008; 23:51.
  60. Porter M, Spear W, Akar JG, et al. Prospective study of atrial fibrillation termination during ablation guided by automated detection of fractionated electrograms. J Cardiovasc Electrophysiol 2008; 19:613.
  61. Katritsis D, Giazitzoglou E, Sougiannis D, et al. Complex fractionated atrial electrograms at anatomic sites of ganglionated plexi in atrial fibrillation. Europace 2009; 11:308.
  62. Hou Y, Scherlag BJ, Lin J, et al. Ganglionated plexi modulate extrinsic cardiac autonomic nerve input: effects on sinus rate, atrioventricular conduction, refractoriness, and inducibility of atrial fibrillation. J Am Coll Cardiol 2007; 50:61.
  63. Hou Y, Scherlag BJ, Lin J, et al. Interactive atrial neural network: Determining the connections between ganglionated plexi. Heart Rhythm 2007; 4:56.
  64. Arora R, Ulphani JS, Villuendas R, et al. Neural substrate for atrial fibrillation: implications for targeted parasympathetic blockade in the posterior left atrium. Am J Physiol Heart Circ Physiol 2008; 294:H134.
  65. Ulphani JS, Arora R, Cain JH, et al. The ligament of Marshall as a parasympathetic conduit. Am J Physiol Heart Circ Physiol 2007; 293:H1629.
  66. Arora R, Ng J, Ulphani J, et al. Unique autonomic profile of the pulmonary veins and posterior left atrium. J Am Coll Cardiol 2007; 49:1340.
  67. Ogawa M, Zhou S, Tan AY, et al. Left stellate ganglion and vagal nerve activity and cardiac arrhythmias in ambulatory dogs with pacing-induced congestive heart failure. J Am Coll Cardiol 2007; 50:335.
  68. Ng J, Villuendas R, Cokic I, et al. Autonomic remodeling in the left atrium and pulmonary veins in heart failure: creation of a dynamic substrate for atrial fibrillation. Circ Arrhythm Electrophysiol 2011; 4:388.
  69. Stavrakis S. Low-level transcutaneous electrical vagus nerve stimulation. J Am Coll Cardiol 2015; :867.
  70. Li D, Fareh S, Leung TK, Nattel S. Promotion of atrial fibrillation by heart failure in dogs: atrial remodeling of a different sort. Circulation 1999; 100:87.
  71. Polyakova V, Miyagawa S, Szalay Z, et al. Atrial extracellular matrix remodelling in patients with atrial fibrillation. J Cell Mol Med 2008; 12:189.
  72. Pellman J, Lyon RC, Sheikh F. Extracellular matrix remodeling in atrial fibrosis: mechanisms and implications in atrial fibrillation. J Mol Cell Cardiol 2010; 48:461.
  73. Corradi D, Callegari S, Maestri R, et al. Heme oxygenase-1 expression in the left atrial myocardium of patients with chronic atrial fibrillation related to mitral valve disease: its regional relationship with structural remodeling. Hum Pathol 2008; 39:1162.
  74. Corradi D, Callegari S, Benussi S, et al. Myocyte changes and their left atrial distribution in patients with chronic atrial fibrillation related to mitral valve disease. Hum Pathol 2005; 36:1080.
  75. Corradi D, Callegari S, Benussi S, et al. Regional left atrial interstitial remodeling in patients with chronic atrial fibrillation undergoing mitral-valve surgery. Virchows Arch 2004; 445:498.
  76. Nakajima H, Nakajima HO, Salcher O, et al. Atrial but not ventricular fibrosis in mice expressing a mutant transforming growth factor-beta(1) transgene in the heart. Circ Res 2000; 86:571.
  77. Lamirault G, Gaborit N, Le Meur N, et al. Gene expression profile associated with chronic atrial fibrillation and underlying valvular heart disease in man. J Mol Cell Cardiol 2006; 40:173.
  78. Lee KW, Everett TH 4th, Rahmutula D, et al. Pirfenidone prevents the development of a vulnerable substrate for atrial fibrillation in a canine model of heart failure. Circulation 2006; 114:1703.
  79. Gutierrez A, Van Wagoner DR. Oxidant and Inflammatory Mechanisms and Targeted Therapy in Atrial Fibrillation: An Update. J Cardiovasc Pharmacol 2015; 66:523.
  80. Harada M, Van Wagoner DR, Nattel S. Role of inflammation in atrial fibrillation pathophysiology and management. Circ J 2015; 79:495.
  81. Youn JY, Zhang J, Zhang Y, et al. Oxidative stress in atrial fibrillation: an emerging role of NADPH oxidase. J Mol Cell Cardiol 2013; 62:72.
  82. Negi S, Sovari AA, Dudley SC Jr. Atrial fibrillation: the emerging role of inflammation and oxidative stress. Cardiovasc Hematol Disord Drug Targets 2010; 10:262.
  83. Kim YM, Guzik TJ, Zhang YH, et al. A myocardial Nox2 containing NAD(P)H oxidase contributes to oxidative stress in human atrial fibrillation. Circ Res 2005; 97:629.
  84. Kim YM, Kattach H, Ratnatunga C, et al. Association of atrial nicotinamide adenine dinucleotide phosphate oxidase activity with the development of atrial fibrillation after cardiac surgery. J Am Coll Cardiol 2008; 51:68.
  85. Bonilla IM, Sridhar A, Györke S, et al. Nitric oxide synthases and atrial fibrillation. Front Physiol 2012; 3:105.
  86. Dudley SC Jr, Hoch NE, McCann LA, et al. Atrial fibrillation increases production of superoxide by the left atrium and left atrial appendage: role of the NADPH and xanthine oxidases. Circulation 2005; 112:1266.
  87. Carnes CA, Chung MK, Nakayama T, et al. Ascorbate attenuates atrial pacing-induced peroxynitrite formation and electrical remodeling and decreases the incidence of postoperative atrial fibrillation. Circ Res 2001; 89:E32.
  88. Shiroshita-Takeshita A, Schram G, Lavoie J, Nattel S. Effect of simvastatin and antioxidant vitamins on atrial fibrillation promotion by atrial-tachycardia remodeling in dogs. Circulation 2004; 110:2313.
  89. Rodrigo R, Korantzopoulos P, Cereceda M, et al. A randomized controlled trial to prevent post-operative atrial fibrillation by antioxidant reinforcement. J Am Coll Cardiol 2013; 62:1457.
  90. Ozaydin M, Icli A, Yucel H, et al. Metoprolol vs. carvedilol or carvedilol plus N-acetyl cysteine on post-operative atrial fibrillation: a randomized, double-blind, placebo-controlled study. Eur Heart J 2013; 34:597.
  91. Atienza F, Almendral J, Moreno J, et al. Activation of inward rectifier potassium channels accelerates atrial fibrillation in humans: evidence for a reentrant mechanism. Circulation 2006; 114:2434.
  92. Allessie, MA, Lammers, WJEP, Bonke, FIM, et, al. Experimental evaluation of Moe's multiple wavelet hypothesis of atrial fibrillation. In: Cardiac Arrhythmias, Zipes, DP, Jalife, J (Eds), Grune and Stratton, Orlando 1985. p.265.
  93. Moe GK. On the multiple wavelet hypothesis of atrial fibrillation. Arch Int Pharmacodyn Ther 1962; 140:183.
  94. Konings KT, Kirchhof CJ, Smeets JR, et al. High-density mapping of electrically induced atrial fibrillation in humans. Circulation 1994; 89:1665.
  95. Kumagai K, Khrestian C, Waldo AL. Simultaneous multisite mapping studies during induced atrial fibrillation in the sterile pericarditis model. Insights into the mechanism of its maintenance. Circulation 1997; 95:511.
  96. Ramanna H, Hauer RN, Wittkampf FH, et al. Identification of the substrate of atrial vulnerability in patients with idiopathic atrial fibrillation. Circulation 2000; 101:995.
  97. Papageorgiou P, Monahan K, Boyle NG, et al. Site-dependent intra-atrial conduction delay. Relationship to initiation of atrial fibrillation. Circulation 1996; 94:384.
  98. Kim BS, Kim YH, Hwang GS, et al. Action potential duration restitution kinetics in human atrial fibrillation. J Am Coll Cardiol 2002; 39:1329.
  99. Konings KT, Smeets JL, Penn OC, et al. Configuration of unipolar atrial electrograms during electrically induced atrial fibrillation in humans. Circulation 1997; 95:1231.
  100. Holm M, Johansson R, Brandt J, et al. Epicardial right atrial free wall mapping in chronic atrial fibrillation. Documentation of repetitive activation with a focal spread--a hitherto unrecognised phenomenon in man. Eur Heart J 1997; 18:290.
  101. Jaïs P, Haïssaguerre M, Shah DC, et al. A focal source of atrial fibrillation treated by discrete radiofrequency ablation. Circulation 1997; 95:572.
  102. Sanders P, Berenfeld O, Hocini M, et al. Spectral analysis identifies sites of high-frequency activity maintaining atrial fibrillation in humans. Circulation 2005; 112:789.
  103. Daoud EG, Pariseau B, Niebauer M, et al. Response of type I atrial fibrillation to atrial pacing in humans. Circulation 1996; 94:1036.
  104. Janse, MJ. Propagation of atrial impulses through the atrioventricular node. In: Atrial Arrhythmias: Current Concepts and Management, Touboul, P, Waldo, AL (Eds), Mosby, St. Louis 1990. p.141.
  105. Hayano J, Sakata S, Okada A, et al. Circadian rhythms of atrioventricular conduction properties in chronic atrial fibrillation with and without heart failure. J Am Coll Cardiol 1998; 31:158.
  106. Fozzard HA, Arnsdorf MF. Cardiac electrophysiology. In: The Heart and Cardiovascular System, Fozzard HA, Haber E, Jennings RB, et al (Eds), Raven Press, New York 1991. p.63.
  107. Fleck RP, Chen PS, Boyce K, et al. Radiofrequency modification of atrioventricular conduction by selective ablation of the low posterior septal right atrium in a patient with atrial fibrillation and a rapid ventricular response. Pacing Clin Electrophysiol 1993; 16:377.
  108. Williamson BD, Man KC, Daoud E, et al. Radiofrequency catheter modification of atrioventricular conduction to control the ventricular rate during atrial fibrillation. N Engl J Med 1994; 331:910.
  109. Della Bella P, Carbucicchio C, Tondo C, Riva S. Modulation of atrioventricular conduction by ablation of the "slow" atrioventricular node pathway in patients with drug-refractory atrial fibrillation or flutter. J Am Coll Cardiol 1995; 25:39.
  110. Kreiner G, Heinz G, Siostrzonek P, Gössinger HD. Effect of slow pathway ablation on ventricular rate during atrial fibrillation. Dependence on electrophysiological properties of the fast pathway. Circulation 1996; 93:277.
  111. Lin WS, Tai CT, Hsieh MH, et al. Catheter ablation of paroxysmal atrial fibrillation initiated by non-pulmonary vein ectopy. Circulation 2003; 107:3176.
  112. Chen SA, Tai CT. Catheter ablation of atrial fibrillation originating from the non-pulmonary vein foci. J Cardiovasc Electrophysiol 2005; 16:229.
  113. Lee SH, Tai CT, Hsieh MH, et al. Predictors of non-pulmonary vein ectopic beats initiating paroxysmal atrial fibrillation: implication for catheter ablation. J Am Coll Cardiol 2005; 46:1054.
  114. Haïssaguerre M, Hocini M, Sanders P, et al. Localized sources maintaining atrial fibrillation organized by prior ablation. Circulation 2006; 113:616.
  115. Ouyang F, Ernst S, Chun J, et al. Electrophysiological findings during ablation of persistent atrial fibrillation with electroanatomic mapping and double Lasso catheter technique. Circulation 2005; 112:3038.
  116. Gerstenfeld EP, Callans DJ, Dixit S, et al. Incidence and location of focal atrial fibrillation triggers in patients undergoing repeat pulmonary vein isolation: implications for ablation strategies. J Cardiovasc Electrophysiol 2003; 14:685.
  117. Nanthakumar K, Plumb VJ, Epstein AE, et al. Resumption of electrical conduction in previously isolated pulmonary veins: rationale for a different strategy? Circulation 2004; 109:1226.
  118. Verma A, Kilicaslan F, Pisano E, et al. Response of atrial fibrillation to pulmonary vein antrum isolation is directly related to resumption and delay of pulmonary vein conduction. Circulation 2005; 112:627.
  119. Pratola C, Baldo E, Notarstefano P, et al. Radiofrequency ablation of atrial fibrillation: is the persistence of all intraprocedural targets necessary for long-term maintenance of sinus rhythm? Circulation 2008; 117:136.
  120. Cappato R, Negroni S, Pecora D, et al. Prospective assessment of late conduction recurrence across radiofrequency lesions producing electrical disconnection at the pulmonary vein ostium in patients with atrial fibrillation. Circulation 2003; 108:1599.
  121. Verma A, Wazni OM, Marrouche NF, et al. Pre-existent left atrial scarring in patients undergoing pulmonary vein antrum isolation: an independent predictor of procedural failure. J Am Coll Cardiol 2005; 45:285.
  122. Aviles RJ, Martin DO, Apperson-Hansen C, et al. Inflammation as a risk factor for atrial fibrillation. Circulation 2003; 108:3006.
  123. Tsikouris JP, Kluger J, Song J, White CM. Changes in P-wave dispersion and P-wave duration after open heart surgery are associated with the peak incidence of atrial fibrillation. Heart Lung 2001; 30:466.
  124. Ishii Y, Schuessler RB, Gaynor SL, et al. Inflammation of atrium after cardiac surgery is associated with inhomogeneity of atrial conduction and atrial fibrillation. Circulation 2005; 111:2881.
  125. Abed HS, Samuel CS, Lau DH, et al. Obesity results in progressive atrial structural and electrical remodeling: implications for atrial fibrillation. Heart Rhythm 2013; 10:90.
  126. Wong CX, Abed HS, Molaee P, et al. Pericardial fat is associated with atrial fibrillation severity and ablation outcome. J Am Coll Cardiol 2011; 57:1745.
  127. Abed HS, Wittert GA, Leong DP, et al. Effect of weight reduction and cardiometabolic risk factor management on symptom burden and severity in patients with atrial fibrillation: a randomized clinical trial. JAMA 2013; 310:2050.
  128. O'Connell RP, Musa H, Gomez MS, et al. Free Fatty Acid Effects on the Atrial Myocardium: Membrane Ionic Currents Are Remodeled by the Disruption of T-Tubular Architecture. PLoS One 2015; 10:e0133052.
  129. Ellinor PT, Yoerger DM, Ruskin JN, MacRae CA. Familial aggregation in lone atrial fibrillation. Hum Genet 2005; 118:179.
  130. Darbar D, Herron KJ, Ballew JD, et al. Familial atrial fibrillation is a genetically heterogeneous disorder. J Am Coll Cardiol 2003; 41:2185.
  131. Lubitz SA, Yin X, Fontes JD, et al. Association between familial atrial fibrillation and risk of new-onset atrial fibrillation. JAMA 2010; 304:2263.
  132. Brugada R, Tapscott T, Czernuszewicz GZ, et al. Identification of a genetic locus for familial atrial fibrillation. N Engl J Med 1997; 336:905.
  133. Chen YH, Xu SJ, Bendahhou S, et al. KCNQ1 gain-of-function mutation in familial atrial fibrillation. Science 2003; 299:251.
  134. Hasegawa K, Ohno S, Ashihara T, et al. A novel KCNQ1 missense mutation identified in a patient with juvenile-onset atrial fibrillation causes constitutively open IKs channels. Heart Rhythm 2014; 11:67.
  135. Bartos DC, Duchatelet S, Burgess DE, et al. R231C mutation in KCNQ1 causes long QT syndrome type 1 and familial atrial fibrillation. Heart Rhythm 2011; 8:48.
  136. Christophersen IE, Olesen MS, Liang B, et al. Genetic variation in KCNA5: impact on the atrial-specific potassium current IKur in patients with lone atrial fibrillation. Eur Heart J 2013; 34:1517.
  137. Olesen MS, Refsgaard L, Holst AG, et al. A novel KCND3 gain-of-function mutation associated with early-onset of persistent lone atrial fibrillation. Cardiovasc Res 2013; 98:488.
  138. Deo M, Ruan Y, Pandit SV, et al. KCNJ2 mutation in short QT syndrome 3 results in atrial fibrillation and ventricular proarrhythmia. Proc Natl Acad Sci U S A 2013; 110:4291.
  139. Olesen MS, Bentzen BH, Nielsen JB, et al. Mutations in the potassium channel subunit KCNE1 are associated with early-onset familial atrial fibrillation. BMC Med Genet 2012; 13:24.
  140. Yang Y, Xia M, Jin Q, et al. Identification of a KCNE2 gain-of-function mutation in patients with familial atrial fibrillation. Am J Hum Genet 2004; 75:899.
  141. Lundby A, Ravn LS, Svendsen JH, et al. KCNE3 mutation V17M identified in a patient with lone atrial fibrillation. Cell Physiol Biochem 2008; 21:47.
  142. Ravn LS, Aizawa Y, Pollevick GD, et al. Gain of function in IKs secondary to a mutation in KCNE5 associated with atrial fibrillation. Heart Rhythm 2008; 5:427.
  143. Darbar D, Kannankeril PJ, Donahue BS, et al. Cardiac sodium channel (SCN5A) variants associated with atrial fibrillation. Circulation 2008; 117:1927.
  144. Olesen MS, Holst AG, Svendsen JH, et al. SCN1Bb R214Q found in 3 patients: 1 with Brugada syndrome and 2 with lone atrial fibrillation. Heart Rhythm 2012; 9:770.
  145. Tucker NR, Ellinor PT. Emerging directions in the genetics of atrial fibrillation. Circ Res 2014; 114:1469.
  146. Hodgson-Zingman DM, Karst ML, Zingman LV, et al. Atrial natriuretic peptide frameshift mutation in familial atrial fibrillation. N Engl J Med 2008; 359:158.
  147. Huang RT, Xue S, Xu YJ, et al. A novel NKX2.5 loss-of-function mutation responsible for familial atrial fibrillation. Int J Mol Med 2013; 31:1119.
  148. Zhou YM, Zheng PX, Yang YQ, et al. A novel PITX2c loss‑of‑function mutation underlies lone atrial fibrillation. Int J Mol Med 2013; 32:827.
  149. Gudbjartsson DF, Arnar DO, Helgadottir A, et al. Variants conferring risk of atrial fibrillation on chromosome 4q25. Nature 2007; 448:353.
  150. Kääb S, Darbar D, van Noord C, et al. Large scale replication and meta-analysis of variants on chromosome 4q25 associated with atrial fibrillation. Eur Heart J 2009; 30:813.
  151. Delaney JT, Jeff JM, Brown NJ, et al. Characterization of genome-wide association-identified variants for atrial fibrillation in African Americans. PLoS One 2012; 7:e32338.
  152. Shi L, Li C, Wang C, et al. Assessment of association of rs2200733 on chromosome 4q25 with atrial fibrillation and ischemic stroke in a Chinese Han population. Hum Genet 2009; 126:843.
  153. Kolek MJ, Parvez B, Muhammad R, et al. A common variant on chromosome 4q25 is associated with prolonged PR interval in subjects with and without atrial fibrillation. Am J Cardiol 2014; 113:309.
  154. Ellinor PT, Lunetta KL, Albert CM, et al. Meta-analysis identifies six new susceptibility loci for atrial fibrillation. Nat Genet 2012; 44:670.
  155. Ellinor PT, Lunetta KL, Glazer NL, et al. Common variants in KCNN3 are associated with lone atrial fibrillation. Nat Genet 2010; 42:240.
  156. Olesen MS, Andreasen L, Jabbari J, et al. Very early-onset lone atrial fibrillation patients have a high prevalence of rare variants in genes previously associated with atrial fibrillation. Heart Rhythm 2014; 11:246.